Immuneering Q3 net loss $0.43/share; Phase 2a for IMM-1-104 expanded to 5 arms

Immuneering Corp

2023-Q3 EPS reported -$1.36

Net loss $12.6M ($0.43/sh) vs $12.8M ($0.49/sh) in Q3 2022.
Cash $97.2M at Sept 30, 2023 ($105.5M at Dec 31, 2022); runway into 2025.
Phase 1 dose evaluation of IMM-1-104 ~2/3 enrolled; no DLTs; Phase 2 dose recommendation expected early 2024.
Phase 2a expanded to 5 arms: 3 monotherapy (PDAC, melanoma, NSCLC) and 2 combinations (mFOLFIRINOX, gem/nab-paclitaxel); first patient dosing early 2024.
IND for IMM-6-415 on track for Q4 2023; Phase 1/2a to include RAS and RAF mutant disease.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immuneering Corp reported for the quarter ended September 30, 2023 results: net income $12.6 million, EPS $0.43 per share.

Period: for the quarter ended September 30, 2023
Net income: $12.6 million
EPS: $0.43 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $12.6 million, or $0.43 per share, for the quarter ended September 30, 2023

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.